How the IL-7 receptor affects multiple sclerosis
Role of IL-7R in CNS autoimmunity
Researchers are testing whether targeting the IL-7 receptor on certain immune cells can reduce the inflammation that drives multiple sclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11237958 on NIH RePORTER |
What this research studies
This research looks at a gene-linked immune receptor called IL-7R that has been tied to multiple sclerosis. Scientists use mouse models that mimic MS and laboratory studies of immune cells to see what happens when IL-7R is removed from dendritic cells. They study how dendritic-cell signals such as Endothelin-1 influence regulatory T cells (IL-9+ Tregs) and how those cells change disease severity. Although most work is in the lab with animals and cells, the findings could point to new targets for treatments or for selecting patients in future clinical studies.
Who could benefit from this research
Good fit: People with multiple sclerosis or individuals known to carry risky IL-7R gene variants would be most relevant to follow or join related future studies.
Not a fit: Patients with non-inflammatory neurological disorders or forms of MS not driven by IL-7R-related pathways are unlikely to benefit directly from this preclinical work.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost protective regulatory T cells or block IL-7R-driven inflammation to reduce MS relapses or progression.
How similar studies have performed: Genetic studies have linked IL-7R to MS and prior mouse EAE experiments show IL-7R influences disease, but the specific dendritic-cell to IL-9+ Treg mechanism described here is a newer, less-tested idea.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rostami, A.m. — Thomas Jefferson University
- Study coordinator: Rostami, A.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.